Scherfler Christoph, Scholz Sonja W, Donnemiller Eveline, Decristoforo Clemens, Oberladstätter Michael, Stefanova Nadia, Diederen Eric, Virgolini Irene, Poewe Werner, Wenning Gregor K
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria.
Neuroimage. 2005 Feb 1;24(3):822-31. doi: 10.1016/j.neuroimage.2004.10.005. Epub 2004 Nov 24.
Single photon emission computed tomography (SPECT) and MRI coregistration have been assessed to characterize striatal dopamine D2/D3 receptor (D2/D3R) availability in rats following injection of the D2 and D3R radioligand [123I] iodobenzamide ([123I]IBZM). High-resolution SPECT data were obtained with a pinhole collimator. In order to precisely estimate brain regions of low radioligand uptake, SPECT images were coregistered onto a MRI template with high accuracy (maximum mismatch 1.1 mm). To evaluate an adequate dose of radioligand to be administered without exceeding the radioligand-to-receptor occupancy >5% and to define an appropriate time period for image acquisition, three untreated groups of animals received 29.6, 37, and 44.4 MBq of [123I]IBZM and underwent five consecutive SPECT acquisitions lasting 64 min each. Ratio calculations between specific striatal radioligand uptake and nondisplaceable cerebellar uptake revealed a secular equilibrium between 75 and 355 min post-tracer application in all three animal groups. Consequently, since the highest regional uptake values were obtained in the animal group receiving 44.4 MBq [123I]IBZM, this injection dose was considered to be appropriate. Finally, the capacity of the imaging method to detect distinct severity levels of striatal dopamine D2/D3 receptor loss was tested in a low, medium, and high dose quinolinic acid (QA) animal model of Huntington's disease. Motor impairment indicative of striatal dysfunction was monitored using amphetamine-induced rotational behavior and locomotor activity. Loss of striatal D2/D3R bearing medium-sized spiny neurons was assessed by DARPP-32 immunohistochemistry and compared to [123I]IBZM binding. Optical density measures of DARPP-32 immunohistochemistry demonstrated QA dose-dependent mild to subtotal unilateral striatal lesions ranging from 29.4% to 96.9% when compared to the nonlesioned side. Linear regression analysis showed that measurements of striatal DARPP-32 optical density and striatal [123I]IBZM uptake of the lesioned side were highly correlated (r2=0.83; P<0.001) whereas correlation with locomotor activity was less tight (r2=0.23; P<0.05; amphetamine-induced rotational behavior was not significantly correlated). This is the first study to demonstrate that in vivo [123I]IBZM SPECT and MRI coregistration are highly sensitive and, in contrast to behavioral measures, accurately detect mild to subtotal striatal lesions by measuring loss of D2/D3R availability. SPECT-MRI-based estimation of regional [123I]IBZM uptake provides a cost effective and widely available in vivo imaging technique for assessing striatal integrity in animal studies.
单光子发射计算机断层扫描(SPECT)与磁共振成像(MRI)配准技术已被用于评估大鼠在注射D2和D3受体放射性配体[123I]碘苯甲酰胺([123I]IBZM)后纹状体多巴胺D2/D3受体(D2/D3R)的可利用性。使用针孔准直器获取高分辨率SPECT数据。为了精确估计放射性配体摄取较低的脑区,SPECT图像以高精度(最大配准误差1.1毫米)配准到MRI模板上。为了评估不超过放射性配体与受体占有率>5%时应给予的放射性配体适当剂量,并确定合适的图像采集时间段,三组未处理的动物分别接受29.6、37和44.4 MBq的[123I]IBZM,并连续进行5次SPECT采集,每次持续64分钟。特异性纹状体放射性配体摄取与不可置换的小脑摄取之间的比值计算显示,在所有三组动物中,示踪剂应用后75至355分钟达到长期平衡。因此,由于在接受44.4 MBq [123I]IBZM的动物组中获得了最高的区域摄取值,该注射剂量被认为是合适的。最后,在亨廷顿舞蹈病的低、中、高剂量喹啉酸(QA)动物模型中测试了该成像方法检测纹状体多巴胺D2/D3受体丢失不同严重程度的能力。使用苯丙胺诱导的旋转行为和运动活性监测指示纹状体功能障碍的运动损伤。通过DARPP-32免疫组织化学评估含有D2/D3R的中等大小棘状神经元的丢失,并与[123I]IBZM结合情况进行比较。DARPP-32免疫组织化学的光密度测量显示,与未损伤侧相比,QA剂量依赖性地导致轻度至几乎完全单侧纹状体损伤,范围为29.4%至96.9%。线性回归分析表明,损伤侧纹状体DARPP-32光密度测量值与纹状体[123I]IBZM摄取高度相关(r2 = 0.83;P < 0.001),而与运动活性的相关性较弱(r2 = 0.23;P < 0.05;苯丙胺诱导的旋转行为无显著相关性)。这是第一项证明体内[123I]IBZM SPECT与MRI配准高度敏感的研究,并且与行为测量方法不同,通过测量D2/D3R可利用性的丧失能准确检测轻度至几乎完全的纹状体损伤。基于SPECT-MRI的区域[123I]IBZM摄取估计为动物研究中评估纹状体完整性提供了一种经济有效且广泛可用的体内成像技术。